NanoSignal

NanoSignal was a development-stage biotechnology company focused on the early detection of cancer through proprietary diagnostic technology. The company's core platform, the NanoSignal test, was designed to identify cancer-specific biomarkers from a single drop of blood by measuring changes in the electrical properties of nanoparticles. This non-invasive approach aimed to provide a rapid and cost-effective screening tool for various malignancies, including breast, prostate, and lung cancers. Despite its innovative goals, the company faced significant operational challenges and regulatory scrutiny, eventually leading to its cessation of active business operations.